Time to read
Lenacapavir could be a game-changer for HIV prevention, but right now it is not being made available as PrEP.
Together with 18 other HIV charities and organisations, we’ve written to NHS England, NHS Wales, NICE and Gilead Sciences to express our shared disappointment and call for action.
A six-monthly injectable option of HIV prevention could make a significant difference for people and communities facing health inequalities and help us get closer to ending new HIV transmissions by 2030.
NICE, NHS England, NHS Wales, and Gilead Sciences still have time to agree on a way forward. We urge them to work together as the NICE process concludes and ensure lenacapavir is available for those who need it.
Read the full letter here.
Letter signatures:
Robbie Currie, CEO, National AIDS Trust
Silvia Petretti, CEO, Positively UK
Sophie Strachan, CEO, Sophia Forum
Richard Angell, OBE, CEO, Terrence Higgins Trust
Rami Ghali, CEO, Brigstowe
Charlotte Cooke, Director of Services, LGBTQ+ Foundation
Mark Santos, CEO, Positive East
Rachel Brett, CEO, Sussex Beacon
Sarah Maslen, Executive Director, Fast Track Cymru
Simon Collins, Co-Founder, i-Base
Darren Knight, CEO, George House Trust
Simon Jones, Co-Founder, Living Well CIC
Michelle Ross, Founder, CliniQ
Anna Brewster, CEO, Food Chain
Joel Robinson, CEO, Spectra CIC
Tom Doyle, CEO, Mesmac
Parminder Sekhon, CEO, Naz
Jeni Hirst, Director of Service Development and Delivery at BHA For Equality
Garry Brough, Chair, UK-CAB